Amalive

For investing or partnering interest, please click here

Realizing the potential of our ammonia scavenger

Amalive is developing potentially life-saving treatment options for hepatic encephalopathy, one of the most common and dangerous complications of advanced liver disease patients.

Hepatic encephalopathy is a continuum of potentially reversible neurological dysfunction caused by build-up of the neurotoxin, ammonia in blood, which cannot be cleared by the damaged liver.

Untreated, HE can result in coma or death. Mortality rates are high at around 50% within 12 months of diagnosis.

Potential to address significant unmet needs

12021 Wong, Robert. et al. “Real-World Trends in the Prevalence of Cirrhosis and Rates of HE Among Commercially Insured Adults in the US 2006-2020”. Clinical & Translational Gastroent., Jan, 2025.
2Ballester, et al. “Natural history of overt HE in cirrhosis patients with acute decompensation” – not published yet.
3Mageed Gl, PSY22. Calculating the prevalence of urea cycle disorders in the EU5 using an incidence-survival model. Value in Health, Vol.18, Issue 7, PA662, Nov 2015

A differentiated approach to HE treatment and prevention

Our ammonia scavenger eliminates ammonia via two synergistic parallel pathways.

This differentiated dual mechanism of action enables ammonia scavenger use for the first time in advanced liver disease.


Formulations for acute and chronic use
Acute Treatment: YAQ006 (IV)
Prevention: YAQ007 (oral)

Our pipeline

Our Leadership

Amalive currently benefits from key members of Yaqrit’s leadership team. In time permanent Amalive appointments will be made.
Prof. Rajiv Jalan, Ph.D. Prof. Rajiv Jalan, Ph.D. Chair, Founder, CMO/CSO

Professor of Hepatology and Head of the Liver Failure Group at UCL. Key opinion leader in advanced liver disease and ACLF, extensively published

Troels Jordansen Troels Jordansen Chief Executive Officer

Over 35 years in commercial and senior leadership roles in life-sciences with an established track record in funding and growing companies

Amrik Shah, ScD in Biostatistics Amrik Shah, ScD in Biostatistics Chief Biomedical Officer

Drug development scientist with expertise in strategic design and analysis of clinical trials, with a specialty in liver disease

Timothy Jenkins, Ph.D. Timothy Jenkins, Ph.D. Chief Development Officer

Experienced research & clinical development leader in biotech and big pharma, with a record of leading teams through to regulatory success

Darren Rubin, MS, MBA Darren Rubin, MS, MBA VP, Innovation Strategy

Over 14 years in pharmaceuticals as a former CSO, chief consultant, and entrepreneur. Track record in strategic development, licensing and BD, and orphan drug product approvals

Karen Church, Ph.D. Karen Church, Ph.D. Head of RA, QA, and Clinical Operations

Clinical and regulatory specialist. Overseen submission of 27 NDAs/MMAs/PMAs and hundreds of INDs/CTAs

Mary-Ann Chang, CFA Mary-Ann Chang, CFA SVP Communications and Strategy

Strategic communicator with more than 25 years of experience in the life-science industry, covering IR, communication and healthcare investment